(1-氨基环己基)-乙酸甲酯 | 178242-64-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (1-氨基环己基)-乙酸甲酯
• 中文别名: 2-(1-氨基环己基)乙酸甲酯
• 英文名称: (1-amino-cyclohexyl)-acetic acid methyl ester
• 英文别名: Methyl 2-(1-aminocyclohexyl)acetate
• CAS: 178242-64-3
• 化学式: C₉H₁₇NO₂
• mdl: MFCD07784119
• 分子量: 171.239
• InChiKey: RLMHBOGYHKMLFN-UHFFFAOYSA-N

物化性质

• 沸点：
  228.9±13.0 °C(Predicted)
• 密度：
  1.007±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  (1-氨基环己基)-乙酸甲酯 在 palladium on activated carbon 氢气 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 32.0h， 生成 [1-(2-amino-phenylamino)-cyclohexyl]-acetic acid methyl ester
  参考文献：
  名称：

  WO2008/147697

  摘要：

  公开号：
• 作为产物：
  描述：

  甲基环己基亚基乙酸酯 在 氨 作用下， 以 甲醇 为溶剂， 生成 (1-氨基环己基)-乙酸甲酯
  参考文献：
  名称：

  Synthesis and structure–activity relationship of a novel, achiral series of TNF-α converting enzyme inhibitors

  摘要：

  A novel series of achiral TNF-alpha converting enzyme (TACE) inhibitors has been discovered. These compounds exhibited activities from 0.35 to 11 nM in a porcine TACE assay and inhibited TNF-alpha production in an LPS-stimulated whole blood assay with an IC50 value of 23 nM for the most potent one. They also have excellent selectivities over related metalloproteases including aggrecanases. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.02.015

文献信息

• [EN] CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] COMPOSÉS INHIBITEURS DE KINASE DÉPENDANT DE LA CYCLINE POUR LE TRAITEMENT D'AFFECTIONS MÉDICALES
  申请人：G1 THERAPEUTICS INC

  公开号：WO2021236650A1

  公开（公告）日：2021-11-25

  This invention is in the area of cell cycle inhibiting compounds for the treatment of disorders involving abnormal cellular proliferation, and include selective CDK2 inhibitors for medical therapy and their pharmaceutically acceptable salts and compositions.

  这项发明涉及细胞周期抑制化合物领域，用于治疗涉及异常细胞增殖的疾病，包括用于医学治疗的选择性CDK2抑制剂及其药用盐和组合物。
• Novel 5-Hydroxytryptamine 4 (5-HT4) Receptor Agonists. Synthesis and Gastroprokinetic Activity of 4-Amino-N (2-(1-aminocycloalkan-1-yl)ethyl)-5-chloro-2 methoxybenzamides.
  作者：Takeshi SUZUKI、Naoki IMANISHI、Hirotsune ITAHANA、Susumu WATANUKI、Keiji MIYATA、Mitsuaki OHTA、Hideaki NAKAHARA、Yoko YAMAGIWA、Toshiyasu MASE

  DOI：10.1248/cpb.46.1116

  日期：——

  A novel series of 4-amino-N-[2-(1-aminocycloalkan-1-yl)ethyl]-5-chloro-2-methoxybenzamide derivatives (1), which had amines conformationally restricted due to the effect of repulsion by neighboring substituents, were prepared and evaluated for 5-hydroxytryptamine 4 (5-HT4) agonistic activities by using the contraction of longitudinal muscle myenteric plexus (LMMP) of guinea pig ileum. One of the most potent compounds in this series was 4-amino-5-chloro-N-[2-(1-dimethylamino-1-cyclohexyl)ethyl]-2-methoxybenzamide (1c, YM-47813) with an EC<50> value of 1.0 μM on LMMP. This compound effectively enhanced gastric motility and gastric emptying in conscious dogs by oral administration (1-3 mg/kg).

  设计合成了一系列具有邻位基团排斥效应使胺基构象受限的4-氨基-N-[2-(1-氨基环烷基-1-基)乙基]-5-氯-2-甲氧基苯甲酰胺衍生物(1)，并采用豚鼠回肠纵肌肠神经丛(LMMP)收缩的方法评价了其5-羟色胺4(5-HT4)激动活性。其中活性最高的是化合物4-氨基-5-氯-N-[2-(1-二甲氨基-1-环己基)乙基]-2-甲氧基苯甲酰胺(1c，YM-47813)，该化合物对LMMP的EC50值为1.0 μM。经口给予麻醉犬(1-3 mg/kg)，该化合物能显著增强胃动力和胃排空。
• Synthesis of Novel Restricted Diamines; 2-(1 -Aminocycloalkan-1-YL)ethylamines
  作者：Takeshi Suzuki、Naoki Imanishi、Hirotsune Itahana、Susumu Watanuki、Mitsuaki Ohta、Toshiyasu Mase

  DOI：10.1080/00397919808005943

  日期：1998.2

  Abstract Novel restricted diamines, 2-(1-aminocycloalkan-1-yl)ethylamines 1, were prepared by using Michael addition of ethyl cyclohexylideneacetate 2 and cycloalkylideneacetonitriles 7 with amines. In Michael addition, ester 2 needed high reaction temperature and gave several products, whereas 7 reacted smoothly and gave 2-(1-amino-1-cyclohexyl)acetonitriles 8 in good yield (NH3 85%, MeNH2 89% EtNH2

  摘要 利用亚环己基乙酸乙酯2和亚环烷基乙腈7与胺的迈克尔加成反应制备了新型受限二胺2-(1-氨基环烷-1-基)乙胺1。在迈克尔加成中，酯 2 需要高反应温度并得到几种产物，而 7 反应平稳并以良好的产率得到 2-(1-氨基-1-环己基)乙腈 8 (NH3 85%, MeNH2 89% EtNH2 80%) 和容易转化为二胺 1。
• [EN] ETHYNYL DERIVATIVES<br/>[FR] DÉRIVÉS D'ÉTHYNYLE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015128307A1

  公开（公告）日：2015-09-03

  The present invention relates to compounds of formula I, wherein Y is N or C-R1'; R1' is hydrogen or F; R1 is hydrogen, halogen or lower alkyl substituted by halogen; R2 is hydrogen or lower alkyl; or R2 forms together with R4 a 6 membered heterocyclic ring containing -CH2-CH2-O-CH2- or -CH2-CH2-NR-C(O)-; R is hydrogen, lower alkyl, phenyl or benzyl; R3 is phenyl or pyridinyl, wherein the N atom in the pyridinyl group may be in different positions; R4' is hydrogen, lower alkyl or lower alkoxyalkyl; R4 is hydrogen, lower alkyl, phenyl optionally substituted by halogen or lower alkoxy, or is cycloalkyl, or is pyridinyl optionally substituted by halogen, lower alkyl, lower alkoxy or =0, or is pyrimidinyl optionally substituted by lower alkyl, lower alkoxy or =0, or is 1 -lower alkyl-pyridinyl, or is pyrazinyl, or is pyridazinyl optionally substituted by lower alkyl, lower alkoxy or =0, or is l-methylpyrrolo[2,3-b]pyridine-5-yl, or is 6-imidazo[l,2- b]pyridazin-6-yl; or R4 forms together with R4' a 4, 5 or 6 membered heterocyclic ring containing -(CH2)5-, -CH2-CH2-O-CH2-CH2-, -CH2-CH2-CH2-, -CH2-CH2-CH2-CH2-, -CH2-O-CH2-CH2- or CH2-CH2-CH2-O-CH2; R5 and R5' are hydrogen or lower alkyl; or R4 forms together with R5 a saturated 5- membered ring containing -CH2-CH2-CH2-; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds may be used for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.

  本发明涉及以下式I的化合物，其中Y为N或C-R1'；R1'为氢或F；R1为氢、卤素或经卤素取代的较低烷基；R2为氢或较低烷基；或R2与R4一起形成一个含有-CH2-CH2-O-CH2-或-CH2-CH2-NR-C(O)-的6元杂环环；R为氢、较低烷基、苯基或苄基；R3为苯基或吡啶基，其中吡啶基中的N原子可能在不同位置；R4'为氢、较低烷基或较低烷氧基烷基；R4为氢、较低烷基、苯基（可选择地经卤素或较低烷氧基取代）、环烷基、或吡啶基（可选择地经卤素、较低烷基、较低烷氧基或=0取代）、或嘧啶基（可选择地经较低烷基、较低烷氧基或=0取代）、或1-较低烷基-吡啶基，或吡嗪基，或吡啶嗪（可选择地经较低烷基、较低烷氧基或=0取代），或1-甲基吡咯并[2,3-b]吡啶-5-基，或6-咪唑并[1,2-b]吡嗪-6-基；或R4与R4'一起形成含有-(CH2)5-、-CH2-CH2-O-CH2-CH2-、-CH2-CH2-CH2-、-CH2-CH2-CH2-CH2-、-CH2-O-CH2-CH2-或CH2-CH2-CH2-O-CH2-的4、5或6元杂环环；R5和R5'为氢或较低烷基；或R4与R5一起形成一个饱和的含有-CH2-CH2-CH2-的5元环；或制药学上可接受的盐或酸加成盐，或消旋混合物，或其相应的对映体和/或光学异构体和/或立体异构体。这些化合物可用于治疗帕金森病、焦虑、恶心、强迫性障碍、自闭症、神经保护、癌症、抑郁症和2型糖尿病。
• Benzimidazolone Chymase Inhibitors
  申请人：Abeywardane Asitha

  公开号：US20100240702A1

  公开（公告）日：2010-09-23

  Disclosed are small molecule inhibitors which are useful in treating various diseases and conditions involving chymase.

  公开了一种小分子抑制剂，其在治疗涉及chymase的各种疾病和病况方面是有用的。